Trial · NCT00551460
Results by group222
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 222
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Continuous Complete Remission at 3 Years | ATRA + GO + Arsenic | 74 | 95% Confidence Interval 62 to 84 | percentage of participants | |
| Mortality Rate at 6 Weeks | ATRA + GO + Arsenic | 11 | 95% Confidence Interval 5 to 21 | percentage of participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | ALT, SGPT (serum glutamic pyruvic transaminase) | 37 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | AST, SGOT | 46 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Acidosis (metabolic or respiratory) | 4 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Acute vascular leak syndrome | 1 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Adult respiratory distress syndrome (ARDS) | 3 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Albumin, serum-low (hypoalbuminemia) | 24 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Alkaline phosphatase | 23 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Alkalosis (metabolic or respiratory) | 4 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Allergic reaction/hypersensitivity | 8 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Allergic rhinitis | 6 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Allergy/Immunology-Other | 1 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Anorexia | 18 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Arthritis (non-septic) | 1 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Ascites (non-malignant) | 2 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Atelectasis | 2 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Atrioventricular block - 2nd degree Mobitz Type II | 1 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Atrioventricular block - first degree | 1 | Participants | |
| Frequency of Toxicities | ATRA + GO + Arsenic | Auditory/Ear-Other | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00551460/results